Sandbox Reserved 1095: Difference between revisions
From Proteopedia
Jump to navigationJump to search
References |
No edit summary |
||
| Line 17: | Line 17: | ||
=== Recent studies === | === Recent studies === | ||
Finally, around 2015, researchers have found the crystal structure of the receptor in complex with its antagonist [https://pubchem.ncbi.nlm.nih.gov/compound/ZD-7155-hydrochloride ZD7155] and with an inverse agonist [https://en.wikipedia.org/wiki/Olmesartan olmesartan]<ref> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705918/ </ref>. [https://en.wikipedia.org/wiki/X-ray_crystallography X-ray cryogenic-crystallography] has been used. They have found similar conformation of the receptor when it is linked to the antagonist or to the inverse agonist. They have also found conserved molecular recognition modes. To complete this discovery, they have realized some experiments with mutants to identify the different residues which interact with the ligand. | Finally, around 2015, researchers have found the crystal structure of the receptor in complex with its antagonist [https://pubchem.ncbi.nlm.nih.gov/compound/ZD-7155-hydrochloride ZD7155] and with an inverse agonist [https://en.wikipedia.org/wiki/Olmesartan olmesartan]<ref> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705918/ </ref>. [https://en.wikipedia.org/wiki/X-ray_crystallography X-ray cryogenic-crystallography] has been used. They have found similar conformation of the receptor when it is linked to the antagonist or to the inverse agonist. They have also found conserved molecular recognition modes. To complete this discovery, they have realized some experiments with mutants to identify the different residues which interact with the ligand. | ||
The structure of this protein have also been solved using an other method called serial femtosecond crystallography, corresponding to the | The structure of this protein have also been solved using an other method called serial femtosecond crystallography, corresponding to the structure [http://proteopedia.org/wiki/index.php/4yay 4YAY]. | ||
== Structure (function relationship) == | == Structure (function relationship) == | ||
| Line 30: | Line 30: | ||
=== G protein-binding site === | === G protein-binding site === | ||
When the angiotensin II binds to the angiotensin receptor in the ligand binding pocket, the conformation of the trans-membrane domain changes to create a cytosolic cleft for the binding and activation of G proteins. In this cleft, several conserved residues can be found, which form functional motifs present in all [[GPCRs]] <ref> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457125/#!po=8.33333 </ref>. | When the angiotensin II binds to the angiotensin receptor in the ligand binding pocket, the conformation of the trans-membrane domain changes to create a cytosolic cleft for the binding and activation of G proteins. In this cleft, several conserved residues can be found, which form functional motifs present in all [[GPCRs]] <ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457125/#!po=8.33333 Singh KD, Unal H, Desnoyer R, Karnik SS. Mechanism of Hormone Peptide Activation of a GPCR: Angiotensin II Activated State of AT1R Initiated by van der Waals Attraction. J Chem Inf Model. 2019;59(1):373–385. doi:10.1021/acs.jcim.8b00583] </ref>. | ||
=== Interaction with drugs === | === Interaction with drugs === | ||
